Vanguard Global Advisers’s Bright Minds Biosciences DRUG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.59K Sell
32
-3,838
-99% -$271K ﹤0.01% 3682
2026
Q2
$272K Buy
3,870
+812
+27% +$63.8K ﹤0.01% 2375
2026
Q1
$223K Buy
+3,058
New +$246K ﹤0.01% 2389

Other funds holding DRUG

Vanguard Global Advisers's DRUG Position: Q3 2026 in Review

Vanguard Global Advisers reduced its Bright Minds Biosciences (DRUG) stake by 99% in Q3 2026, selling an estimated $271K and leaving 32 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #3682.

Vanguard Global Advisers first reported a position in DRUG in Q1 2026 and has held it in 3 quarters since. The position peaked at $272K in Q2 2026. 110 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

  • Vanguard Global Advisers held 32 shares of Bright Minds Biosciences worth $1.59K as of Q3 2026.
  • Vanguard Global Advisers sold 3,838 Bright Minds Biosciences shares in Q3 2026, an estimated $271K.
  • Bright Minds Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3682 holding.
  • Vanguard Global Advisers first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Bright Minds Biosciences position peaked at $272K in Q2 2026.
  • 110 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.